Stay updated on Nivolumab Combo in Early Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Combo in Early Lung Cancer Clinical Trial page.

Latest updates to the Nivolumab Combo in Early Lung Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedPage revision updated to v3.5.0 (replacing v3.4.3).SummaryDifference0.0%

- Check16 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe study record now shows Terminated due to slow accrual and lack of funding, and results have been posted. The summary also includes the Major Pathologic Response (mpCR) definition and related outcome measures.SummaryDifference3%

- Check44 days agoChange DetectedAdded Revision: v3.4.2. The prior government funding/status notice (Revision: v3.4.1) was removed.SummaryDifference0.4%

- Check51 days agoChange DetectedAdded a site-wide notice about potential delays due to a lapse in government funding and updated the page revision to v3.4.1; the previous revision v3.4.0 was removed.SummaryDifference0.4%

- Check58 days agoChange DetectedThe glossary is now shown by default and the QC status label has been updated to 'Last Update Submitted that Met QC Criteria' with a new version reference v3.4.0. The previous label 'Last Update Submitted that met QC Criteria', the 'No FEAR Act data' label, and the older version reference v3.3.4 were removed.SummaryDifference0.2%

Stay in the know with updates to Nivolumab Combo in Early Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Combo in Early Lung Cancer Clinical Trial page.